However, few studies have compared the effects of different esas on anemia in identical predialysis ckd patients. Erythropoiesis stimulating agents medical clinical. The dose frequency, depending on the patients condition, can vary from once in a week or once every two weeks. The maximum dosage of erythropoietin should not exceed a total of 60,000 units per week 5. Therapeutic class overview erythropoiesisstimulating agents. Erythropoiesis stimulating agents injectable medication. This and related erythropoiesisstimulating agents esas greatly benefited patients by decreasing debilitating symptoms, improving their quality of life, and freeing them from dependence on blood transfusions with their associated complications such as. Thrombopoiesis stimulating agents are used to stop bleeding to treat chronic itp and hepatitis c. Erythropoiesisstimulating agent administration and. Drugs, such as epoetin alpha and darbepoetin alpha used to stimulate red cell production in anaemia.
Medical policy revisions erythropoietin stimulating agents. A wide range of erythropoiesisstimulating agents to stimulate red blood cell production are currently in clinical use, but advances in our understanding of erythropoiesis have provided an ever. The erythropoiesis stimulating agents, epoetin alfa epogenprocrit, amgen and darbepoetin alfa aranesp, amgen can increase hemoglobin levels and subsequently reduce fatigue and the. Benefits and harms of erythropoiesisstimulating agents for anemia related to cancer. Interpretation of blood tests and appropriate dose adjustments remains the responsibility of the renal unit.
Renal anemia is a wellrecognized complication of chronic kidney disease ckd, and the deficiency of erythropoietin. Erythropoiesis stimulating agents esas boost the production of red blood cells and as. New dosing guidelines for erythropoiesisstimulating agents. Recombinant erythropoietin is a manmade version of natural erythropoietin. Anemia is a common finding in cancer patients and can be a result of treatment or of underlying disease 1. Esa monitoring policy, effective october 1, 2006 pdf esa monitoring policy, effective april 1, 2006 pdf chapter 11 end stage renal disease esrd pdf chapter 8 outpatient esrd hospital, independent. Erythropoietin analogs contain the identical amino acid sequence as naturally occurring erythropoietin, and have the same biological effect. Erythropoietin clinical trials, 944 results, page 1. Erythropoiesisstimulating agents in the management of. Approved september 18, 20 medical policy revisions erythropoietin stimulating agents esas updated the name of the policy. Evidencebased recommendations on erythropoiesisstimulating agents epoetin alfa eprex, epoetin beta neorecormon, epoetin theta, epoeitin zeta retacrit and darbepoetin alfa aranesp for treating anaemia in adults with cancer having chemotherapy the recommendations also apply to biosimilar products of the technologies that have a marketing authorisation allowing the use. Esas in the united states provides a classic example of how economics drive practice. Erythropoiesis stimulating agents esas boost the production of red blood cells and as such may play a role in optimising red cell mass pbm pillar 1 in specific groups of patients.
A phase iii, multicentre, openlabel, sequentialcohort, dose escalation study evaluated the efficacy and safety of romiplostim in thrombocytopenic patients with low or intermediate1risk mds. Cms has policies that effect the use of erythropoietin stimulating agents in esrd facilities. Pdf erythropoiesisstimulating agents in renal medicine. It is produced by cloning the gene for erythropoietin. An erythropoietin stimulating agent esa is an analog of erythropoietin. Erythropoiesisstimulating agents should be discontinued after 6 to 8 weeks in nonresponders. June 24, 2011 the us food and drug administration fda today urged more conservative dosing guidelines for erythropoiesisstimulating agents. Erythropoiesisstimulating agents esa are medications which stimulate the bone marrow to make red blood cells. Erythropoiesis stimulating agents injectable medication precertification request aetna precertification notification 503 sunport lane, orlando, fl 32809. Aetna considers erythropoiesis stimulating agents experimental and investigational for all other indications, including the following conditions, because its use in these. Erythropoiesisstimulating agents esa are medications which stimulate the bone marrow to. Name erythropoiesisstimulating agents accession number dbcat002721 description not available drugs. This article was updated on june 20, 20, to reflect current web addresses. Aranesp darbepoetin alfa epogen, procrit epoetin alfa mircera methoxy polyethylene glycolepoetin beta retacrit epoetin alfaepbx i.
Effects of three kinds of erythropoiesisstimulating. But, if the hemoglobin level approaches or goes over 11 gdl, the dose of the drug should be. Increasing incidence of anemia cases worldwide is driving the growth of. All three erythropoiesisstimulating agents the two recombinant erythropoietins epogen and procrit and the. The purpose of this medical policy is to provide a guide to coverage. Erythropoiesis stimulating agents and other growth factors. At, we keep tabs on over 200,000 clinical trials in the us and abroad, using medical data supplied directly by the us national institutes of health. Therapeutic class overview erythropoiesisstimulating agents therapeutic class overviewsummary. Erythropoiesisstimulating agents are used to treat anemia and kidney disease.
Recombinant human erythropoietin was first used clinically. The administration of erythropoiesisstimulating agents. Epo is a protein hormone 165 amino acids primarily synthesized by the kidneys that contains 3 n glycan and 1 o glycan side chain. Erythropoiesisstimulating agents in the treatment of. Fdas announcement applies to patients with earlystage kidney. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease article pdf available in patient preference and adherence 2. Erythropoiesisstimulating agents prices and information. Local medicare contractors may continue to make reasonable and necessary determinations on all other uses of esas not specified in this ncd.
Application for erythropoietinstimulating agents world health. Erythropoiesis stimulating agents esas are abused by athletes because they increase the oxygencarrying capacity of the blood by stimulating red blood cell production 25. Erythropoietin production in patients with chronic renal. Erythropoiesis stimulating agents esas this article contains instructions for coding medical necessity in accordance with both the national coverage determination ncd and local coverage determination lcd and other cms instructions on darbepoetin alfa aranesp, dpa and epoetin alfa epogen, procrit, epo. Median survival was significantly shorter with darbepoetin than with placebo. Erythropoiesis stimulating agents esas in cancer and related neoplastic conditions ncd 110. Chicagopatients with cancer are at risk for developing anemia. A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
Nothing in this medical policy is intended to discourage or prohibit providing other medical advice or treatment. The use of epoetin alfa, darbepoetin, or pegylated pegepoetin beta may be considered medically necessary for. Erythropoiesis stimulating agents esa includes the following products. Treatment is indicated for patients at high risk for perioperative transfusions with significant, anticipated blood loss, for example, for patients expected to lose greater than two units of blood. Erythropoetin stimulating agents for the treatment for. Erythropoiesisstimulating agent esa nova scotia health authority. The treatment of cancerassociated anemia remains a challenge, given that the most effective therapy for it erythropoiesisstimulating agents esas can also increase the risk for thromboembolic events. Safety concerns of erythropoiesis stimulating agents esas. The economic realities of erythropoiesisstimulating agent therapy in. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in hivaids.
Outcomes showed that use of esas significantly reduced the relative risk of red blood cell transfusions risk ratio rr 0. Key messages y esas are a method of optimising red cell mass pbm pillar 1 y esas are an authority item on the pharmaceutical benefits scheme pbs with a limited. In these situations they decrease the need for blood transfusions. A largescale audit of blood transfusions in 2719 cancer patients showed that 38% had a hemoglobin level below 11. The original intent of our analysis was to evaluate risks for vte when cancer patients received esas vs placebocontrol. Pdf erythropoietin stimulating agents in the management. Epoetin alfa and darbepoetin alfa are erythropoiesis stimulating agents esas, approved for the treatment of anemia low red blood cells resulting from chronic kidney disease, chemotherapy. Erythropoiesisstimulating agents market global industry.
Pdf the cloning of the epo gene in the early 1980s allowed for the development of recombinant. Who eml 20162017 erythropoietinstimulating agents december 2016. Chronic kidney disease ckd anemia treatment was revolutionized in the late 1980s with the introduction of recombinant human erythropoietin. The safety of erythropoiesisstimulating agents for the. This chart is created by aggregating the total number of claims for the drugs in this class divided by. These drugs are given by injection shot and work by stimulating the production of more red blood cells. Traumatic brain injury continues to be the leading cause of death and disability in children and young adults. Although the introduction of erythropoiesisstimulating agents esas. Erythropoiesisstimulating agents esas are standard therapy for chronic kidney disease ckd patients with renal anemia. Seventynine patients who switched from epoetin beta to darbepoetin alfa group 1, and 82 patients who switched from darbepoetin alfa to epoetin beta pegol. Treatment of anemia associated with chronic kidney disease if. Dosing, uses, side effects, interactions, patient handouts, pricing and more from medscape reference. Esa monitoring policy, effective october 1, 2006 pdf.
Esas are biologically engineered hormones produced by recombinant dna technology. See the medicare benefit policy manual, chapter 11, section 90 and chapter 15, section 50. Erythropoiesis stimulating agents esas in cancer and. Erythropoiesis stimulating agents 2 high risk for perioperative transfusions with significant, anticipated blood loss, for example, for patients expected to lose greater than two units of blood. Safety concerns of erythropoiesis stimulating agents esas i. These drugs are given by injection shot and work by. Erythropoetin stimulating agents for the treatment for renal anaemia information for primary care management of renal anaemia is coordinated by the anaemia nurse practitioner based at hull and east yorkshire hospitals nhs trust. Reimbursement policy erythropoiesis stimulating agents. Pdf clinical pharmacokinetics and pharmacodynamics of. Information on erythropoiesisstimulating agents esa. Erythropoiesisstimulating agents clinical criteria information included in this document erythropoiesisstimulating agents aranesp drugs requiring prior authorization. Erythropoiesisstimulating agents in renal medicine article pdf available in the oncologist 16 suppl 3suppl 3. This policy addresses the following erythropoiesisstimulating agents esas. In the case of anaemia caused by anticancer chemotherapy, research in the late 1990s and subsequently has suggested that the risks associated with such treatment include thromboembolic disease and promotion.
Who eml 20162017 application for erythropoietinstimulating agents erythropoietin type blood factors pdf. This medical policy is not intended to dictate to providers how to practice medicine. Epoetin alfa epogen, procrit, epoetin alfa epbx retacrit are considered medically necessary. Recombinant erythropoietin drugs are known as erythropoietinstimulating agents esas. Erythropoiesis stimulating agents esas in cancer and related neoplastic conditions. These agents are given as subcutaneous injections or as intravenous injections. The erythropoiesisstimulating agents esas epoetin alfa and darbepoetin are indicated for the treatment of anemia caused by endstage renal disease esrd, zidovudine therapy in patients with hiv, chemotherapy in cancer patients, and also to reduce transfusion need in patients scheduled for noncardiac major surgery. They work by increasing red blood cells in the blood. When erythropoiesisstimulating agents esas are covered.
1261 1561 731 1557 1556 1339 1398 911 321 1255 588 1411 344 1681 195 992 777 1527 1608 1364 1332 769 733 1467 1085 327 254 1359 1351 1189 552 1059 318 227 705 37 1044 924 795 618 605 260